Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.
about
Left ventricular assist device implantation strategies and outcomesVentricular assist devices and non-cardiac surgeryVentricular assist devices: pharmacological aspects of a mechanical therapyComplications of Continuous-Flow Mechanical Circulatory Support Devices.Pump thrombosis-A riddle wrapped in a mystery inside an enigma.Primary anticoagulation with bivalirudin for patients with implantable ventricular assist devices.Heparin induced thrombocytopenia with mechanical circulatory support devices: review of the literature and management considerations.Thrombolytics in VAD management - A single-center experienceMedical management of patients with continuous-flow left ventricular assist devices.Mechanical circulatory support as a bridge to transplant or for destination therapy.Preoperative patient optimization for mechanical circulatory supportCurrent status of mechanical circulatory support: a systematic review.Close antiplatelet therapy monitoring and adjustment based upon thrombelastography may reduce late-onset bleeding in HeartMate II recipients.Pharmacotherapy for mechanical circulatory support: a comprehensive review.Cerebrovascular complications of left ventricular assist devices.Management of patients with implanted ventricular assist devices for noncardiac surgery: a clinical review.Clinical management for complications related to implantable LVAD use.Management of pump thrombosis in patients with left ventricular assist devices.Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis.Coagulopathy in Mechanical Circulatory Support: A Fine Balance.Left ventricular assist device exchange: the Toronto General Hospital experienceStroke and Intracranial Hemorrhage in HeartMate II and HeartWare Left Ventricular Assist Devices: A Systematic Review.Point-of-Care Rapid-Seeding Ventricular Assist Device with Blood-Derived Endothelial Cells to Create a Living Antithrombotic Coating.Evaluation and treatment of pump thrombosis and hemolysis.Implantation of rotary blood pumps into 115 patients: a single-centre experience.Ventricular contractility and compliance measured during axial flow blood pump support: in vitro study.Control of the Fluid Viscosity in a Mock Circulation.Diagnosis of LVAD Thrombus using a High-Avidity Fibrin-Specific 99mTc Probe.Prevention and Treatment of Thrombotic and Hemorrhagic Complications in Patients Supported by Continuous-Flow Left Ventricular Assist Devices.Management of anticoagulation and antiplatelet therapy in patients with left ventricular assist devices.Left coronary artery occlusion caused by a large thrombus on the left coronary cusp in a patient with a continuous-flow ventricular assist device.Results of the prospective multicenter Japanese bridge to transplant study with a continuous-flow left ventricular assist device.
P2860
Q26770316-720D9DD3-C023-4B6B-B3CE-2E9A824DEA8DQ26774702-8ACBE9DA-6D58-4C05-8777-E3ABCEB367D9Q27002612-5FA75882-C2D6-4ABE-B658-44D6CD5B7C93Q30409848-C069CBF6-2F40-44B8-90C0-D71C9628A506Q30423801-D17772D4-44C9-45B9-B784-450F008A7828Q33410802-A0E596EA-B090-4532-B67A-34681FC2206AQ33440296-19575C3F-F3AF-489F-BA8C-D93F4CAAFE70Q33773690-81527813-1634-40C8-8A5D-C8703CA5E1F7Q34152572-D14914F6-3EB9-4934-9E89-DA557CCB85B3Q34268754-BBB5A501-9D71-4F59-8BF5-D745FF426DE3Q34604471-EB4FDC69-8B5F-4F79-8ABA-8ACE5FD604FAQ36206550-D1E8C165-60A7-487C-880F-7C615F68146CQ37642744-FF3E8DF2-B39E-4430-9AD8-FB24B8CAFFB9Q37826020-1E06DA2F-9C18-4D92-B39D-C5FDF3F2830EQ38015693-CDF84B99-A080-4116-BE94-BDA480B8D82DQ38153202-81A1DD52-0DD3-496F-B6F6-A958B7D1F760Q38265076-C66B997F-F4F2-44D9-8075-7FA176D11C2CQ38310801-81C9B15D-CF77-4C55-9270-5E257FE6EC85Q38572789-B3E24E17-2817-41CB-8547-5072F7DA2DC4Q38611535-02FB6682-6114-4C67-A50B-16FD271A4B41Q38754195-7369A262-565D-4867-9D52-3019CCD8FF04Q39190576-13C2D230-FF33-4E20-B95F-1C37D68DCDCFQ41968551-522FBC91-7830-41D9-8A91-924C93DC19E8Q43002925-F040DBF7-B1E8-4176-B3C6-9E3E00E6AA81Q43827183-729780C8-3B77-4DEC-84E2-1E99F94696FCQ44154102-49C2814F-1FF5-4346-8A31-7CF9D40D1BD6Q47912237-1036C124-4752-421B-AF94-089B5AC4FED6Q49788040-73562242-A5BA-4F55-A264-7A153940A2C5Q50093815-3B2AE3D6-B7F3-4AA7-A153-CEBAC1FBE4ACQ50987110-A7FC3C72-07F6-4BDD-A1EA-4F8D53E6BFF1Q51162187-8179DE6C-032F-4409-9384-A6227BD46992Q51756276-D707F756-10DD-4CAC-B591-C3B1A4A578A6
P2860
Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Post-operative heparin may not ...... to long-term warfarin therapy.
@en
Post-operative heparin may not ...... to long-term warfarin therapy.
@nl
type
label
Post-operative heparin may not ...... to long-term warfarin therapy.
@en
Post-operative heparin may not ...... to long-term warfarin therapy.
@nl
prefLabel
Post-operative heparin may not ...... to long-term warfarin therapy.
@en
Post-operative heparin may not ...... to long-term warfarin therapy.
@nl
P2093
P1476
Post-operative heparin may not ...... to long-term warfarin therapy.
@en
P2093
Andrew Boyle
David J Farrar
Francis D Pagani
John V Conte
Kartik S Sundareswaran
Keith D Aaronson
Mark S Slaughter
Ranjit John
Stuart D Russell
Yoshifumi Naka
P304
P356
10.1016/J.HEALUN.2010.02.003
P577
2010-04-18T00:00:00Z